Use of cell free DNA in breast oncology

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1865, Issue 2, 2016, Pages 266-274

  Canzoniero, Jenna VanLiere ^a   Park, Ben Ho ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Breast cancer; Cell free DNA; Circulating tumor DNA; Mutation

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CELL FREE DNA; CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; TUMOR MARKER;

BREAST CANCER; BREAST SURGERY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CIRCULATING TUMOR CELL; DNA CONTENT; DNA DETERMINATION; EARLY DIAGNOSIS; GENE MUTATION; GENOME SIZE; HUMAN; NEXT GENERATION SEQUENCING; PATIENT MONITORING; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SURVIVAL TIME; TREATMENT RESPONSE; BLOOD; BREAST NEOPLASMS; FEMALE; GENETICS; MUTATION; PROGNOSIS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; MUTATION; PROGNOSIS;

EID: 84962258871     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2016.03.006     Document Type: Review

References (82)

1. Mandel P., Metais P. Les acides nucléiques du plasma sanguin chez l'homme. C. R. Soc. Seances Soc. Biol. Fil. 1948, 142:241-243.
2. Gormally E., Caboux E., Vineis P., Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat. Res. 2007, 635:105-117.
3. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977, 37:646-650.
4. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 2014, 32:579-586.
5. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agarwal N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6(224).
6. Jung K., Fleischhacker M., Rabien A. Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin. Chim. Acta 2010, 411:1611-1624.
7. Schwarzenbach H., Hoon D.S.B., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426.
8. Snyder M.W., Kircher M., Hill A., Daza R.M., Shendure J. Cell-free DNA comprises and in vivo nucleosome footprint that informs its tissues-of-origin. Cell 2016, 164:57-68.
9. Choi J., Reich C.F., Pisetsky D.S. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 2005, 115:55-62.
10. Wong H.Y., Park B.H. Plasma tumor DNA: on your markers, get set, go!. Ann. Transl. Med. 2014, 2(1):2.
11. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61:1659-1665.
12. Madic J., Kiialainen A., Bidard F., Birzele F., Ramey G., Leroy Q., et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int. J. Cancer 2014, 136:2158-2165.
13. De Mattos-Arruda L., Cortes J., Santarpia L., Vivancos A., Tabernero J., Reis-Filho J.S., et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat. Rev. Clin. Oncol. 2013, 10:377-389.
14. El Messaoudi S., Rolet F., Mouliere F., Thierry A.R. Circulating cell free DNA: preanalytical considerations. Clin. Chim. Acta 2013, 424:222-230.
15. Lee T., Montalvo L., Chrebtow V., Busch M.P. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 2001, 41:276-282.
16. Vallee A., Marcq M., El Kouri C., Lacroiz H., Bennouna J., Denis M.G. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer 2013, 82:373-374.
17. Benesova L., Belsanova B., Suchanek S., Kopeckova M., Minarikova P., Lipska L., et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal. Biochem. 2013, 433:227-234.
18. Beaver J.A., Jelovac D., Balukrishna S., Cochran R.L., Croessman S., Zabransky D.J., et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin. Cancer Res. 2014, 20(10):2643-2650.
19. Forshew T., Murtaza M., Parkinson C., Gale D., Tsui D.W.Y., Kaper F., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 2012, 4(136):136ra68.
20. Diehl F., Li M., He Y., Kinzler K.W., Vogelstein B., Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat. Methods 2006, 3:551.
21. Board R.E., Wardley A.M., Dixon J.M., Armstrong A.C., Howell S., Renshaw L., et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res. Treat. 2010, 120:461-467.
22. Higgins M.J., Jelovac D., Barnathan E., Blair B., Slater S., Powers P., et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 2012, 18(12):3462-3469.
23. Jorgensen K.J., Gotzsche P.C. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. Br. Med. J. 2009, 339:b2587.
24. Zanetti-Dallenbach R., Wight E., AX Fan, Lapaire O., Hahn S., Holzgreve W., et al. Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Anticancer Res. 2008, 28:921-926.
25. Umetani N., Giuliano A.E., Hiramatsu S.H., Amersi F., Nakagawa T., Martino S., et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J. Clin. Oncol. 2006, 24:4270-4276.
26. Iqbal S., Vishnubhatla S., Raina V., Sharma S., Gogia A., Deo S.S.V., et al. Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer. SpringerPlus 2015, 4:2265.
27. Madhavan D., Wallwiener M., Bents K., Zucknick M., Nees J., Schott S., et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res. Treat. 2014, 146:163-174.
28. Wu X., Tanaka H. Aberrant reduction of telomere repetitive sequences in plasma cell-free DNA for early breast cancer detection. Oncotarget 2015, 6(30):29795.
29. Chimonidou M., Tzitzira A., Strati A., Sotiropoulou G., Sfikas C., Malamos N., et al. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin. Biochem. 2013, 46:235-240.
30. Dulaimi E., Hillinck J., de Caceres I.I., Al-Saleem T., Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin. Cancer Res. 2004, 10:6189-6193.
31. Oshiro C., Kagara N., Naoi Y., Shimoda M., Shimomura A., Maruyama N., et al. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res. Treat. 2015, 150:299-307.
32. Schwarzenbach H., Muller V., Milde-Langosch K., Steinbach B., Pantel K. Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Mol. Biosyst. 2011, 7:2848-2854.
33. Leary R.J., Sausen M., Kinde I., Papadopoulos N., Carpten J.D., Craig D., et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 2012, 4:162.
34. Fujita N., Nakayama T., Yamamoto N., Kim S.J., Shimazu K., Shimomura A., et al. Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Oncology 2012, 83:273-282.
35. Bechman T., Andersen R.F., Pallisgaard N., Madsen J.S., Maae E., Jakobsen E.H., et al. Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer. J. Cancer Res. Clin. Oncol. 2013, 139:995-1003.
36. Huang Z.H., Li L.H., Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 2006, 243:64-70.
37. Garcia J.M., Garcia V., Silva J., Pena C., Dominguez G., Sanchez A., et al. Extracellular tumor DNA in plasma and overall survival in breast cancer patients. Gene Chromosome Cancer 2006, 45:692-701.
38. Lehner J., Stotzer O.J., Fersching D., Nagel D., Holdenrieder S. Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy. Clin. Chim. Acta 2013, 425:206-211.
39. Dawson S., Tsui D.W.Y., Murtaza M., Biggs H., Rueda O.M., Chin S., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 368:1199-1209.
40. Garcia-Murillas I., Schiavon G., Weigelt B., Ng C., Hrebien S., Cutts R.J., et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 2014, 7(302):1-11.
41. Olsson E., Winter C., George A., Chen Y., Howlin J., Tang M.E., et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EBMO Mol. Med. 2015, 7:1034-1047.
42. Arnedos M., Vicier C., Loi S., Lefebvre C., Michiels S., Bonnefoi H., et al. Precision medicine for metastatic breast cancer-limitations and solutions. Nat. Rev. Clin. Oncol. 2015, (Advance online publication).
43. Martelotto L.G., Ng C.K.Y., Piscuoglio S., Weigelt B., Reis-Filho J.S. Breast cancer intra-tumor heterogeneity. Breast Cancer Res. 2014, 16(3):210.
44. Aparicio S., Caldas C. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 2013, 368(9):842-851.
45. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366(10):883-892.
46. De Mattos-Arruda L., Weigelt B., Cortes J., Won H.H., Ng C.K.Y., Nuciforo P., et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 2014, 25:1729-1735.
47. Butler T.M., Johnson-Camacho K., Peto M., Wang N.J., Macey T.A., Korkola J.E., et al. Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease. PLOS One 2015, 10(8).
48. Frenel J.S., Carreira S., Goodall J., Roda D., Perez-Lopez R., Tunariu N., et al. Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration. Clin. Cancer Res. 2015, OF1.
49. Murtaza M., Dawson S., Tsui D.W.Y., Gale D., Forshew T., Piskorz A.M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
50. Isakoff S.J., Engelman J.A., Irie H.Y., Brachmann S.M., Pearline R.V., Cantley L.C., et al. Brease cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005, 65:10992.
51. Toy W., Shen Y., Won H., Green B., Sakr R.A., Will M., et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 2013, 45:1439.
52. Merenbakh-Lamin K., Ben-Baruch N., Yeheskel A., Dvir A., Soussan-Gutman L., Jeselsohn R., et al. D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013, 73:6856.
53. Jeselsohn R., Yelensky R., Buchwalter G., Frampton G., Meric-Bernstam F., Gonzalez-Angulo A.M., et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 2014 Apr 1, 20(7):1757-1767.
54. Li S., Shen D., Shao J., Crowder R., Liu W., Prat A., et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013, 4:1116-1130.
55. Robinson D.R., Wu Y., Vats P., Su F., Lonigro R.J., Cao X., et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 2013, 45:1446-1451.
56. Chu D., Paoletti C., Gersch C., VanDenBerg D.A., Zabransky D.J., Cochran R.L., et al. ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients. Clin. Cancer Res. 2015.
57. Sefrioui D., Perdrix A., Sarafan-Vasseur N., Dolfus C., Dujon A., Picquenot J., et al. Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Int. J. Cancer 2015, 137:2513-2519.
58. Guttery D.S., Page K., Hills A., Woodley L., Marchese S.D., Rghebi B., et al. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin. Chem. 2015, 61(7):974-982.
59. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2016/03, 351(8):781-791. 2004 08/19.
60. CellSearch circulating tumor cell kit [Internet]. Available from:. http://documents.cellsearchctc.com/pdf/e631600001/e631600001_EN.pdf.
61. Van Poznak C., Somerfield M.R., Bast R.C., Cristofanilli M., Goetz M.P., Gonzalez-Angulo A.M., et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American society of clinical oncology clinical practice guideline. J. Clin. Oncol. 2015 August 20, 33(24):2695-2704.
62. Bidard F., Proudhon C., Pierga J. Circulating tumor cells in breast cancer. Mol. Oncol. 2016 3, 10(3):418-430.
63. Haber D.A., Velculescu V.E. Blood-based analyses of cancer: circulating tumor cells and circulating tumor dna. Cancer Discov. 2014, 4:650.
64. Bidard F., Weigelt B., Reis-Filho J.S. Going with the flow: from circulating tumor cells to DNA. Sci. Transl. Med. 2013, (American Association for the Advancement of Science;5(207):207 ps14-).
65. Alix-Panabières C., Pantel K. Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA. Ann. Transl. Med 2013, 1(2).
66. Agassi R., Czeiger D., Shaked G., Avriel A., Sheynin J., Lavrenkov K., et al. Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast cancer. Am. J. Clin. Pathol. 2015, 143:18-24.
67. Iressa: EPAR-product information [Internet] Available from:. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001016/human_med_000857.jsp&mid=WC0b01ac058001d124.
68. Woods J.L. Document number: GEN1500674 2015.
69. Board R.E., Thelwell N.J., Ravetto P.F., Little S., Ranson M., Dive C., et al. Multiplexed assays for detection of mutations in PIK3CA. Clin. Chem. 2008 April 01, 54(4):757-760.
70. Madic J., Piperno-Neumann S., Servois V., Rampanou A., Milder M., Trouiller B., et al. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin. Cancer Res. 2012 July 15, 18(14):3934-3941.
71. Li M., Diehl F., Dressman D., Vogelstein B., Kinzler K.W. BEAMing up for detection and quantification of rare sequence variants. Nat. Methods 2006, 3:95.
72. Hindson B.J., Ness K.D., Masquelier D.A., Belgrader P., Heredia N.J., Makarewicz A.J., et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 2011 11/15, 83(22):8604-8610.
73. Kinde I., Wu J., Papadopoulos N., Kinzler K.W., Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. U. S. A. 2011 05/17, 108(23):9530-9535.
74. Schmitt M.W., Kennedy S.R., Salk J.J., Fox E.J., Hiatt J.B., Loeb L.A. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl. Acad. Sci. 2012 September 04, 109(36):14508-14513.
75. Fox E.J., Reid-Bayliss K.S., Emond M.J., Loeb L.A. Accuracy of next generation sequencing platforms. Next Gen. Seq. Appl. 2014, 1:1000106.
76. Leary R.J., Kinde I., Diehl F., Schmidt K., Clouser C., Duncan C., et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2010, 2:20.
77. Catarino R., Ferreira M.M., Rodrigues H., Coelho A., Nogal A., Sousa A., et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 2008, 27(8):415-421.
78. El Tarhouny S., Seefeld M., Fan A.X.-, Hahn S., Holzgreve W., Zhong X.Y. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. Cytokine 2008, 44:65-69.
79. Skvortsova T.E., Rykova E.Y., Tamkovich S.N., Bryzgunova O.E., Starikov A.V., Kuznetsova N.P., et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br. J. Cancer 2006, 94:1492-1495.
80. Gong B., Xue J., Yu J., Li H., Hu H., Yen H., et al. Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer. Oncol. Lett. 2012, 3:897-900.
81. Hashad D., Sorour A., Ghazal A., Talaat I. Free circulating tumor DNA as a diagnostic marker for breast cancer. J. Clin. Lab. Anal. 2012, 26:467-472.
82. Kohler C., Radpour R., Barekati Z., Asadollahi R., Bitzer J., Wight E., et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol. Cancer 2009, 8:105.